CJC-1295 with DAC

CJC-1295 with DAC is a synthetic peptide analog designed for research applications. This formulation combines the potent growth hormone-releasing properties of CJC-1295 with the extended half-life enhancement provided by des-Gly-(Nle25),Arg38)-human growth hormone-releasing hormone (D-Ala2, Nle3, D-Phe5, Trp8, Arg10, Pro13, Nle14)-hGHRH(1-29). CJC-1295 with DAC is utilized in preclinical studies to investigate growth hormone dynamics, tissue regeneration, and metabolic processes in animal models.

Research Context

CJC-1295 is a well-characterized peptide analog known for its ability to stimulate growth hormone secretion. Originally developed to enhance growth hormone levels in clinical research settings, its effects on tissue regeneration, wound healing, and metabolic parameters have been explored in animal studies. The inclusion of DAC (des-Gly-(Nle25),Arg38)-human growth hormone-releasing hormone (D-Ala2, Nle3, D-Phe5, Trp8, Arg10, Pro13, Nle14)-hGHRH(1-29)) enhances the peptide’s stability, allowing for prolonged action in vivo. This combination is critical for researchers investigating the physiological and pharmacological effects of growth hormone stimulation in animal models.

Research Overview

CJC-1295 with DAC is widely employed in preclinical research to study growth hormone secretion dynamics, tissue repair mechanisms, and metabolic regulation. Its extended half-life and potent activity make it a valuable tool for longitudinal studies assessing the role of growth hormone in developmental biology, aging research, and regenerative medicine. Researchers often utilize this peptide analog in combination with other experimental treatments to elucidate mechanisms underlying growth and homeostasis.

Key Research Focus Areas

• Growth Hormone Signaling: Investigation of growth hormone receptor-mediated pathways in animal models, including effects on protein synthesis, muscle growth, and bone development.
• Tissue Regeneration: Studies on wound healing, cartilage repair, and organ regeneration, where CJC-1295 with DAC enhances endogenous growth hormone activity.
• Metabolic Regulation: Evaluation of its impact on glucose metabolism, lipolysis, and energy homeostasis in preclinical settings.
• Neuroprotection and Aging Research: Exploration of potential neuroprotective effects in models of neurodegeneration or aging-related declines in growth hormone function.
• Comparative Pharmacology: Comparative analysis of CJC-1295 with DAC versus native growth hormone-releasing peptides to assess efficacy and pharmacokinetic differences.

CJC-1295 with DAC is supplied for research use only and should be handled in accordance with standard laboratory safety protocols. Researchers must adhere to institutional guidelines and regulatory requirements governing peptide use in animal studies.

Safety and Compliance Statement

This peptide is intended solely for scientific and academic investigation in a controlled research environment. Misuse or unauthorized distribution is strictly prohibited. Users must ensure compliance with applicable ethical and regulatory standards, including those pertaining to animal welfare and experimental design. For research use only. Not for human or animal consumption.